Targets › ROS1
12 programs from 12 companies in 41 trials: 20 Phase 2, 12 Phase 1, 7 Phase 3, 2 Phase 4; Oncology; next expected readout Jan 2027.
Receptor tyrosine kinase (RTK) that plays a role in epithelial cell differentiation and regionalization of the proximal epididymal epithelium. NELL2 is an endogenous ligand for ROS1. (UniProt, P08922)
Open in Phaseline: the race on ROS1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Pfizer | crizotinib Hepatocyte growth factor receptor inhibitor; ALK tyrosine kinase receptor inhibitor; EML4-ALK inhibitor | MET, ALK, EML4, NPM1, ROS1 | Phase 4 | NSCLC | Mar 2028 |
| IDEAYA Biosciences | Crizotinib Hepatocyte growth factor receptor inhibitor; ALK tyrosine kinase receptor inhibitor; EML4-ALK inhibitor | MET, ALK, EML4, NPM1, ROS1 | Phase 3 | Uveal Melanoma; Metastatic Uveal Melanoma; ALK Gene Rearrangement; Advanced Lymphoma … | Jan 2027 |
| Roche | Entrectinib (RXDX-101) Neurotrophic tyrosine kinase receptor inhibitor; Proto-oncogene tyrosine-protein kinase ROS inhibitor; ALK tyrosine kinase receptor inhibitor | NTRK1, NTRK2, NTRK3, ROS1, ALK | Phase 3 | Non-Small Cell Lung Cancer; Carcinoma, Non-Small-Cell Lung; Breast Cancer; Solid Tumors … | Jan 2027 |
| Bristol-Myers Squibb | Repotrectinib Nerve growth factor receptor Trk-A inhibitor; Neurotrophic tyrosine kinase receptor type 2 inhibitor; Proto-oncogene tyrosine-protein kinase ROS inhibitor | NTRK1, NTRK2, ROS1, NTRK3, CD74 | Phase 3 | Carcinoma, Non-Small-Cell Lung | Feb 2027 |
| Nuvation Bio | Taletrectinib Proto-oncogene tyrosine-protein kinase ROS inhibitor; Neurotrophic tyrosine kinase receptor inhibitor | ROS1, NTRK1, NTRK2, NTRK3 | Phase 3 | Non Small Cell Lung Cancer; Non-small Cell Lung Cancer (NSCLC) | Jun 2027 |
| Pingping Song | WX-0593 ALK and ROS1 tyrosine kinase inhibitor | ALK, ROS1 | Phase 2 | Non-Small Cell Lung Cancer(NSCLC) | Mar 2027 |
| Ascentage Pharma Group | APG-2449 Multi-targeted tyrosine kinase inhibitor; FAK, ALK, and ROS1 inhibitor | FAK, ALK, ROS1 | Phase 1 | Platinum-resistant Recurrent Ovarian Cancer; Advanced Solid Cancer | May 2027 |
| Xuanzhu Biopharmaceutical | XZP-5955 tablets NTRK and ROS1 fusion inhibitor | NTRK1, NTRK2, NTRK3, ROS1 | Phase 1 | Locally Advanced or Metastatic Solid Tumors | Jun 2027 |
| Turning Point Therapeutics | Repotrectinib (TPX-0005) Nerve growth factor receptor Trk-A inhibitor; Neurotrophic tyrosine kinase receptor type 2 inhibitor; Proto-oncogene tyrosine-protein kinase ROS inhibitor | NTRK1, NTRK2, ROS1, NTRK3, CD74 | Phase 1 | Locally Advanced Solid Tumors; NSCLC; NSCLC Stage IV; Advanced Cancer | Sep 2027 |
| Avistone Biotechnology | ANS03 ROS1 and NTRK tyrosine kinase inhibitor | ROS1, NTRK | Phase 1 | Locally Advanced or Metastatic Solid Tumors Harboring a ROS1 or NTRK Alteration | Dec 2027 |
| Guangzhou JOYO Pharma | JYP0322 ROS1 tyrosine kinase inhibitor | ROS1 | Phase 1 | Protein Kinase Inhibitors | Dec 2027 |
| Nuvalent | Zidesamtinib (NVL-520) ROS1 inhibitor | ROS1 | Phase 1 | Locally Advanced Solid Tumor | Dec 2027 |
Advanced Lymphoma (4) Non Small Cell Lung Cancer (3) Non-Small Cell Lung Cancer (2) Carcinoma, Non-Small-Cell Lung (2) Solid Tumors (2) Haematological Malignancy (2) Locally Advanced Solid Tumors (2) NSCLC (2) Uveal Melanoma (1) Metastatic Uveal Melanoma (1) ALK Gene Rearrangement (1) Non-small Cell Lung Cancer (1)
small molecule (12)
IDEAYA Biosciences (1) Xuanzhu Biopharmaceutical (1) Pingping Song (1) Nuvation Bio (1) Roche (1) Ascentage Pharma Group (1) Turning Point Therapeutics (1) Bristol-Myers Squibb (1) Guangzhou JOYO Pharma (1) Nuvalent (1) Pfizer (1) Avistone Biotechnology (1)
ALK (5) NTRK1 (5) NTRK2 (5) NTRK3 (5) MET (2) EML4 (2) NPM1 (2) CD74 (2) FAK (1) NTRK (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.